South Seas Centre, 75 Mody Road, Tsim Sha Tsui, Kowloon, Hong Kong
[email protected]
+1 (209) 597-3212
Discover advanced LED therapy insights, expert tips, and the latest in device innovation for effective, reliable skincare.
Introduction: Understanding Light's Dual Nature in Health
The relationship between light and human health presents a fascinating paradox. While excessive ultraviolet (UV) radiation exposure is a primary risk factor for melanoma—one of the most serious forms of skin cancer—controlled applications of specific light wavelengths have emerged as powerful therapeutic tools in modern medicine.
This duality underscores the critical importance of understanding not just the dangers of harmful light exposure, but also the remarkable healing potential of safe, therapeutic light applications. As we advance our knowledge of phototherapy, we're discovering new ways to harness light's beneficial properties while protecting ourselves from its harmful effects.
Melanoma awareness campaigns continue to emphasize the importance of sun protection and early detection. Simultaneously, researchers and clinicians are developing increasingly sophisticated light-based treatments that offer hope for various medical conditions. This convergence of prevention and innovation represents a significant opportunity to improve public health outcomes.
This report provides an evidence-based examination of phototherapy—focusing on its two primary modalities: Photobiomodulation (PBM) and Photodynamic Therapy (PDT). By exploring the underlying science, clinical applications, and safety protocols of these approaches, we aim to help readers make informed decisions about light-based health interventions. Through understanding both the risks and benefits of light exposure, we can better navigate the complex landscape of modern phototherapy while maintaining the highest standards of safety and efficacy.
To fully understand the potential and risks of phototherapy, it is essential to first clearly distinguish between two often-conflated core technologies. While both use light, their biological objectives and mechanisms of action are polar opposites. One aims to stimulate cellular vitality and promote repair; the other is designed to selectively destroy target cells. This fundamental difference is the foundation for understanding all subsequent clinical applications and safety considerations.
Photobiomodulation (PBM), formerly known as low-level laser therapy (LLLT), is a non-thermal, non-invasive treatment that typically uses light-emitting diodes (LEDs) or low-power lasers to emit red light (approx. 620-700 nm wavelength) and near-infrared (NIR) light (approx. 700-1440 nm).12 Its core mechanism of action lies in the absorption of photons of specific wavelengths by cellular chromophores, the most critical target being Cytochrome C Oxidase (CCO) in the mitochondrial respiratory chain.15
This photon absorption triggers a cascade of cellular biological events, which can be termed the "mitochondrial cascade":
These primary effects further trigger a wide range of downstream effects, including reducing inflammation by regulating cytokines (e.g., lowering pro-inflammatory interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)), promoting cell proliferation and migration, and synthesizing new proteins (like collagen), which are the biological basis for its applications in wound healing, tissue repair, and skin rejuvenation.15
In complete contrast to the restorative goal of PBM, Photodynamic Therapy (PDT) is a precise, destruction-oriented treatment strategy. It is a strict two-step process, not merely shining light:
The mechanism of action is that when the photosensitizer absorbs the photon energy of a matching wavelength, it becomes activated and transfers this energy to surrounding oxygen molecules, generating highly reactive singlet oxygen and other forms of reactive oxygen species (ROS).33 These strong oxidizing agents are extremely toxic to cells, rapidly destroying cell membranes, mitochondria, and other organelles, leading to the apoptosis or necrosis of the target cells.29 This process is known as phototoxicity.
Therefore, the fundamental goal of PDT is to achieve selective cell killing to treat cancer, clear infections, or eliminate abnormal tissue, whereas the goal of PBM is to promote cellular health and tissue repair through biostimulation.33 Common photosensitizers include aminolevulinic acid (ALA), Methylene Blue, and Riboflavin, which require activation by different colors of light (such as blue or red).29
Before delving into specific applications, it is crucial to understand a core scientific principle of PBM efficacy: the "biphasic dose response," also known as the Arndt-Schulz Law.16 This principle states that the effect of PBM is not linearly incremental—it is not a case of "more is better." Instead, it follows a "Goldilocks" optimal window: if the dose is too low, the light fails to produce a significant biological effect; at a moderate dose, the optimal therapeutic effect is achieved; and if the dose is too high, the effect may diminish, or even become inhibitory or harmful. The mechanism behind this phenomenon may be related to ROS production: moderate ROS are important signaling molecules, but excessive ROS can trigger oxidative stress and cellular damage.
This principle has profound implications for clinical practice and the proliferation of at-home devices. Consumers, when purchasing or using at-home PBM devices, often fall into a common misconception that "higher power is better" or "longer exposure is more effective." However, this logic might inadvertently push them beyond the optimal therapeutic window, not only failing to achieve the desired benefits but potentially inhibiting the cellular repair process. This highlights that the precise control of phototherapy parameters (including wavelength, power density/irradiance, energy density/fluence, and exposure time) is as important as the light itself, and is the core value of professional medical guidance over unregulated home use.
Table 1: Comparative Overview of Photobiomodulation (PBM) and Photodynamic Therapy (PDT)
Treatment of certain skin cancers, actinic keratosis, acne, antimicrobial infections 39
By combining the scientific principles of phototherapy with the context of Brandon Blackstock's condition, we can see that light plays a complex and contradictory role in the field of cancer treatment. On one hand, PDT offers a precise means of attack; on the other, PBM presents a stark warning due to its biostimulatory properties.
Photodynamic Therapy (PDT) is a well-established therapy approved by the U.S. Food and Drug Administration (FDA) for treating specific cancers and precancerous lesions.39 It is particularly suitable for treating lesions on or just under the skin, such as actinic keratosis (a precancerous condition) and certain types of non-melanoma skin cancers (like basal cell carcinoma and squamous cell carcinoma).39 Additionally, PDT can be used to relieve symptoms caused by some internal cancers, for example, when esophageal cancer obstructs the esophagus, PDT can be used to remove tumor tissue to restore swallowing function.32
The main advantage of PDT is its high degree of targeting. The photosensitizer tends to accumulate in rapidly proliferating abnormal cells, and the light is precisely focused on the tumor area, which minimizes damage to surrounding healthy tissue and typically leaves no scars, which is particularly important for treating facial skin cancers.31 However, PDT also has its inherent limitations. Its primary constraint is the limited penetration depth of light, which can usually only penetrate about 1 centimeter (about 1/3 inch) of tissue.29 This means PDT cannot effectively treat large or deep-seated tumors.
Although Brandon Blackstock suffered from melanoma, and PDT is currently more commonly used for other types of skin cancer, the core principle embodied by this therapy—using light to selectively destroy malignant cells—stands in stark contrast to the potential risks of PBM, providing a crucial reference for understanding the dual role of phototherapy in oncology.
This report must convey a critically important safety message: Photobiomodulation (PBM) is strictly contraindicated for direct application over known or suspected malignant lesions.40 This contraindication is not arbitrary but is based on the profound biological mechanisms of PBM itself.
The scientific rationale is that the core function of PBM is to promote cellular bioactivity. It provides energy to cells by increasing ATP production, stimulates cell proliferation and migration, and promotes the formation of new blood vessels (angiogenesis) to improve blood supply.15 Unfortunately, these are the very physiological processes that tumors rely on for growth, invasion, and metastasis. Therefore, applying a biostimulatory therapy to a malignant tumor carries a significant theoretical risk of "fueling the fire," potentially accelerating the tumor's progression. Some in vitro studies have already shown that, under specific parameters, PBM can indeed increase the proliferation rate of cancer cell lines.45
However, this contraindication is not absolute. PBM does have a place in oncology, but its application is highly specific and nuanced. It is used to treat the side effects of cancer treatment itself, serving as a palliative or supportive care measure.43 For example, patients receiving radiation to the head and neck or high-dose chemotherapy often suffer from severe oral mucositis (redness, swelling, pain, and ulcers in the mouth, tongue, and lips), and PBM has been proven effective in preventing and treating this side effect.13 In this context, PBM is precisely applied to the damaged healthy mucosal tissue to reduce inflammation, alleviate pain, and promote healing, while strictly avoiding known tumor areas. All such applications must be conducted under the close supervision and with the permission of an oncologist.42
With the booming market for at-home PBM devices, a potential public health risk is emerging. For diagnosed cancer patients, who are typically under the supervision of the healthcare system, the risk of directly applying PBM to a tumor is relatively controlled. However, the greatest danger lies with ordinary consumers who have undiagnosed malignancies.
Consider this scenario: a person notices a new, unevenly colored, or irregularly bordered spot on their skin, sometimes accompanied by mild pain or discomfort—this perfectly matches the "ABCDE" self-check rule for early melanoma.2 However, instead of seeking immediate medical attention, they mistake it for a common "age spot," an "inflamed mole," or a "sore muscle." At the same time, for reasons of "wellness," "skin rejuvenation," or "pain relief," they may purchase an at-home red light therapy device.24 Believing the advertised claims of "reducing inflammation and promoting healing," they begin to irradiate the unknown skin lesion daily. In doing so, they are unwittingly providing potential cancer cells with the key elements they need to grow: extra cellular energy (ATP), enhanced local blood supply, and stimulated proliferation signals. Theoretically, this could accelerate the tumor's growth and progression, thereby missing the golden window for early diagnosis and treatment. Brandon Blackstock's battle with aggressive melanoma tragically underscores the extreme importance of timely, professional diagnosis for any suspicious skin lesion, especially before considering the use of any form of at-home "health" therapy.
Having established the strict limitations of PBM in oncology, this section will explore its broad applications and evidence base in numerous non-cancerous disease areas, showcasing its potential as a versatile therapeutic modality.
The application of PBM in dermatology is one of its most extensively researched and well-evidenced fields.
The anti-inflammatory and analgesic effects of PBM make it a highly attractive non-pharmacological therapy in the field of pain management.
Lyme disease is a bacterial infectious disease caused by Borrelia burgdorferi, transmitted through tick bites.65 Its clinical manifestations are diverse, with the characteristic "bull's-eye" Erythema migrans often appearing in the early stages. If not treated promptly, it can progress to late-stage Lyme disease affecting the joints, heart, and nervous system.65
A highly challenging and controversial area is "Post-Treatment Lyme Disease Syndrome" (PTLDS). Approximately 10-20% of patients, after receiving standard antibiotic treatment, continue to experience long-term, debilitating symptoms such as diffuse pain, severe fatigue, and cognitive dysfunction (commonly known as "brain fog").70 The National Institutes of Health (NIH) has acknowledged the existence of PTLDS and is funding research into its potential causes, with hypotheses including difficult-to-detect persistent infection, an autoimmune response triggered by the initial infection, or persistent immune dysregulation.75
In the treatment of Lyme disease, there are two mainstream but divergent clinical guidelines. The guidelines from the Infectious Diseases Society of America (IDSA) typically recommend a short course of antibiotics for 10-28 days and strongly oppose the use of long-term antibiotics for PTLDS patients, citing a lack of evidence for efficacy and potential risks.76 In contrast, the International Lyme and Associated Diseases Society (ILADS) emphasizes the importance of clinical diagnosis, advocates for individualized treatment based on the patient's specific situation, is open to long-term antibiotic therapy, and encourages the integration of complementary and alternative therapies to manage persistent symptoms.81
It is within the comprehensive treatment framework advocated by ILADS that phototherapy has begun to be explored as a non-pharmacological means of managing PTLDS symptoms. The known mechanisms of PBM—reducing systemic inflammation, alleviating muscle and nerve pain, combating chronic fatigue by boosting ATP production, and improving microcirculation—are highly consistent with the core needs of PTLDS patients.28 Some clinicians and patients have reported that using PBM (especially whole-body irradiation or targeted application to specific painful areas) helps improve their quality of life.88 Additionally, there are more cutting-edge explorations attempting to use photodynamic therapy (PDT) in combination with photosensitizers like riboflavin to directly kill potentially latent
Borrelia burgdorferi, but research in this area is still in its very early stages and lacks solid clinical evidence.91
When we examine the application of PBM in a variety of seemingly unrelated conditions such as skin aging, muscle fatigue, chronic pain, and even PTLDS, a common, deep biological theme gradually emerges: mitochondrial dysfunction. Skin aging is directly related to a decline in mitochondrial function 20; muscle fatigue is essentially ATP depletion and mitochondrial stress 28; and the core symptom of chronic fatigue syndrome and PTLDS—an indescribable exhaustion—is also hypothesized to be related to mitochondrial energy metabolism disorders.72 The core target of PBM is precisely the mitochondria, and its primary effect is to optimize their function and enhance energy output.16 Therefore, PBM can be understood as a practical form of "mitochondrial medicine." It is not merely a symptomatic treatment for isolated symptoms but addresses the common pathophysiological basis of many chronic, degenerative diseases by repairing the most fundamental energy production units of the cell. This perspective provides a unified scientific framework for understanding why PBM can exhibit such a broad therapeutic potential.
Table 2: Summary of Evidence for PBM Clinical Applications
With the popularization of phototherapy technology, a large number of at-home devices targeting ordinary consumers have flooded the market, from LED masks to handheld wands and large panels. This "at-home revolution" provides people with convenient health management tools but also brings serious challenges regarding efficacy, safety, and misleading marketing. This section aims to provide consumers with a clear navigation map.
The most fundamental difference between professional medical-grade devices and at-home consumer-grade devices lies in their technical parameters, which directly determine the depth and speed of the therapeutic effect.
When purchasing at-home medical devices, consumers often encounter marketing terms like "FDA Certified" or "FDA Approved," but these terms have vastly different meanings at the regulatory level, and understanding their true significance is crucial.98
Although PBM is generally considered very safe, any effective therapy has potential risks and contraindications that users must take seriously.
Table 3: Key Contraindications and Safety Precautions for Phototherapy
When we return to the story of Brandon Blackstock, it is not to speculate on his personal treatment choices, but to draw lessons from his experience in memory of his life. His battle with melanoma, in the most tragic way, underscores the seriousness of skin health and the irreplaceable importance of seeking professional medical diagnosis and care. His story serves as a powerful backdrop for understanding the complexity of phototherapy—light can be both the cause of disease and a tool for healing.
The core message of this report is to reveal the profound duality of phototherapy. On one hand, Photobiomodulation (PBM) demonstrates extraordinary, scientifically-backed potential to heal tissues, reduce inflammation, and combat aging by stimulating the body's own cellular energy and repair mechanisms. On the other hand, Photodynamic Therapy (PDT) provides a precisely guided "molecular scalpel" capable of targeting and destroying diseased cells. It must be clear that these two technologies are fundamentally different in their goals and mechanisms, and any "phototherapy" concept that conflates them is inadequate and potentially misleading.
With technological advancements, phototherapy is moving from professional clinical settings into countless homes, undoubtedly bringing unprecedented opportunities for health management. However, beneath the dawn of hope lies the shadow of misunderstanding and misuse. The proliferation of at-home devices demands a higher level of scientific literacy and caution from consumers. The final call of this report is to embrace an evidence-based, prudent consumerism. The promise of phototherapy technology is real, but the science behind it is complex. Whether for treating disease or enhancing wellness, the powerful force of light is best harnessed under the guidance of qualified medical professionals who can navigate its complexities, ensure its safe application, and distinguish scientific fact from marketing hyperbole. Only then can we truly and safely bask in the therapeutic light of light.
